nach oben

Tumor Biology

Erschienen in:

09.10.2015 | Original Article

HNRNPC as a candidate biomarker for chemoresistance in gastric cancer

verfasst von: Hao Huang, Yong Han, Cheng Zhang, Jian Wu, Junnan Feng, Like Qu, Chengchao Shou

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Chemoresistance is a major cause of treatment failure and high mortality in advanced gastric cancer (AGC). Currently, the mechanism of chemoresistance remains unclear, and there is no biomarker to accurately predict the efficacy of chemotherapy. In the present study, we established human gastric cancer (GC) cell lines resistant to 5-fluorouracil (5FU), paclitaxel (TA), or cisplatin (DDP) by gradient drug treatment and generated a novel monoclonal antibody 5B2 targeting heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) overexpressed in chemoresistant GC cells. Overexpressing HNRNPC in GC cells promoted chemoresistance, and knockdown of HNRNPC by small interfering RNA (siRNA) reversed chemoresistance. By utilizing available datasets, we demonstrated that high level of HNRNPC transcript indicated poor overall survival (OS) and free of progression (FP). HNRNPC expression was negatively correlated with OS of GC patients treated with 5FU-based drugs and with time to progression (TTP) of GC patients treated with CF regimen. These data suggest the potential usefulness of HNRNPC as a prognostic and therapeutic marker of GC.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed

Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidem Biomar. 2014;23(5):700–13.

Lustosa SA, Saconato H, Atallah AN, Lopes Filho Gde J, Matos D. Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials. Acta Cir Bras. 2008;23(6):520–30.

Garrido M, Fonseca PJ, Vieitez JM, Frunza M, Lacave AJ. Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer. Expert Rev Anticancer Ther. 2014;14(8):887–900.CrossRefPubMed

Kim JG. Molecular targeted therapy for advanced gastric cancer. Korean J Intern Med. 2013;28(2):149–55.CrossRefPubMedPubMedCentral

Wong R, Cunningham D. Optimising treatment regimens for the management of advanced gastric cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2009;20(4):605–8.CrossRef

Geng R, Li J. Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother. 2015;16(1):117–22.CrossRefPubMed

Zheng L, Tan W, Zhang J, Yuan D, Yang J, Liu H. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. Cancer Immunol Immunother CII. 2014;63(6):581–6.CrossRefPubMed

Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010;6(4):527–37.CrossRefPubMed

10.

Krueger P, Nitz C, Foster R, MacDonald C, Gelber O, Lalehzadeh G, et al. A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells. Cancer Immunol Immunother CII. 2003;52(6):367–77.PubMed

11.

Mattes MJ, Look K, Furukawa K, Pierce VK, Old LJ, Lewis Jr JL, et al. Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells. Cancer Res. 1987;47(24 Pt 1):6741–50.PubMed

12.

Yin BW, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 2008;8:3.PubMedPubMedCentral

13.

Zhao W, Wang L, Han H, Jin K, Lin N, Guo T, et al. 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel alpha2delta1 subunit. Cancer Cell. 2013;23(4):541–56.CrossRefPubMed

14.

Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004;5(5):292–302.CrossRefPubMed

15.

Butte A. The use and analysis of microarray data. Nat Rev Drug Discov. 2002;1(12):951–60.CrossRefPubMed

16.

Szoke D, Gyorffy A, Surowiak P, Tulassay Z, Dietel M, Gyorffy B. Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer. Onkologie. 2007;30(8–9):421–6.PubMed

17.

Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, et al. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One. 2011;6(2):e16694.CrossRefPubMedPubMedCentral

18.

Kim JG, Chung HY, Yu W. Recent advances in chemotherapy for advanced gastric cancer. World J Gastrointest Oncol. 2010;2(7):287–94.CrossRefPubMedPubMedCentral

19.

Shekhar MP. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets. 2011;11(5):613–23.CrossRefPubMed

20.

Xu HW, Xu L, Hao JH, Qin CY, Liu H. Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer. J Int Med Res. 2010;38(1):34–42.CrossRefPubMed

21.

Cascinu S, Graziano F, Del Ferro E, Staccioli MP, Ligi M, Carnevali A, et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. 1998;83(9):1917–22.CrossRefPubMed

22.

Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. Oncol Rep. 2005;14(3):609–15.PubMed

23.

Shen XM, Zhou C, Lian L, Li LQ, Li W, Tao M. Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer. Cell Biochem Biophys. 2014.

24.

Canadas I, Rojo F, Taus A, Arpi O, Arumi-Uria M, Pijuan L, et al. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(4):938–50.CrossRef

25.

Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–84.CrossRefPubMed

26.

Yoon JH, Ahn SG, Lee BH, Jung SH, Oh SH. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1. Biochem Pharmacol. 2012;83(6):747–57.CrossRefPubMed

27.

Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One. 2013;8(5):e65309.CrossRefPubMedPubMedCentral

28.

Burd CG, Swanson MS, Gorlach M, Dreyfuss G. Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc Natl Acad Sci U S A. 1989;86(24):9788–92.CrossRefPubMedPubMedCentral

29.

Liang CR, Leow CK, Neo JC, Tan GS, Lo SL, Lim JW, et al. Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics. 2005;5(8):2258–71.CrossRefPubMed

30.

Rajagopalan LE, Westmark CJ, Jarzembowski JA, Malter JS. hnRNP C increases amyloid precursor protein (APP) production by stabilizing APP mRNA. Nucleic Acids Res. 1998;26(14):3418–23.CrossRefPubMedPubMedCentral

31.

Lee SY, Park JH, Kim S, Park EJ, Yun Y, Kwon J. A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin-binding proteins in response to DNA double-strand breaks. Biochem J. 2005;388(Pt 1):7–15.CrossRefPubMedPubMedCentral

32.

Christian KJ, Lang MA, Raffalli-Mathieu F. Interaction of heterogeneous nuclear ribonucleoprotein C1/C2 with a novel cis-regulatory element within p53 mRNA as a response to cytostatic drug treatment. Mol Pharmacol. 2008;73(5):1558–67.CrossRefPubMed

33.

Blume SW, Jackson NL, Frost AR, Grizzle WE, Shcherbakov OD, Choi H, et al. Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES. Exp Mol Pathol. 2010;88(3):341–52.CrossRefPubMedPubMedCentral

34.

Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A. 1993;90(23):11217–21.CrossRefPubMedPubMedCentral

35.

Park YM, Hwang SJ, Masuda K, Choi KM, Jeong MR, Nam DH, et al. Heterogeneous nuclear ribonucleoprotein C1/C2 controls the metastatic potential of glioblastoma by regulating PDCD4. Mol Cell Biol. 2012;32(20):4237–44.CrossRefPubMedPubMedCentral

Titel: HNRNPC as a candidate biomarker for chemoresistance in gastric cancer
verfasst von: Hao Huang
Yong Han
Cheng Zhang
Jian Wu
Junnan Feng
Like Qu
Chengchao Shou
Publikationsdatum: 09.10.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4144-1

Springer Medizin

HNRNPC as a candidate biomarker for chemoresistance in gastric cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Curcumin induces apoptosis in p53-null Hep3B cells through a TAp73/DNp73-dependent pathway

Differential function and regulation of orphan nuclear receptor TR3 isoforms in endothelial cells

Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo

CD41 and CD45 expression marks the angioformative initiation of neovascularisation in human haemangioblastoma

XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma

Enantiomeric CopA3 dimer peptide suppresses cell viability and tumor xenograft growth of human gastric cancer cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie